45.Hammerle CW, Crowe SE. When to reconsider the diagnosis
of irritable bowel syndrome. 46.2011; 40: 291-307.
Gastroenterol Clin North AmRubin GHungin P. The diagnosis of IBS in primary care: consensus, De Wit N, Meineche-Schmidt V, Seifert B, Hall N,
development using nominal group technique. Fam Pract47.2006; 23: 687-692.
Zimmerman J. Extraintestinal symptoms in irritable bowel
syndrome and inflammatory bowel diseases: nature,severity, and relationship to gastrointestinal symptoms. 48.Dis SciKeller J, Wedel T, Seidl H, 2003; 48: 743-749.
DigSociety for Digestive and Metabolic Diseases (DGVS) andet al.S3 guideline of the German
the German Society for Neurogastroenterology and Motility(DGNM) to the definition, pathophysiology, diagnosis andtreatment of intestinal motility. Z Gastroenterol2011; 49:49.374-390.
Grundmann O, Yoon SLepidemiology, diagnosis and treatment: an update for health-. Irritable bowel syndrome:
care practitioners. J Gastroenterol Hepatol2010; 25: 691-50.699.
Chang JYirritable bowel syndrome: from pathophysiology to, Talley NJ. Current and emerging therapies in
51.treatment. Konturek PC, Brzozowski T, Konturek SJ. Gut clock:
Trends Pharmacol Sci2010; 31: 326-334.
implication of circadian rhythms in the gastrointestinal tract.52.J Physiol PharmacolBleser S. Alosetron for severe diarrhea-predominant irritable
2011; 62: 139-150.
bowel syndrome: improving patient outcomes. Curr Med53.Res OpinLirritable bowel syndrome: safety and efficacy in perspective.ewis JH. Alosetron for severe diarrhoea-predominant
2011; 27: 503-512.
54.Expert Rev Gastroenterol HepatolPimentel M, Lembo A, Chey WD, 2010; 4: 13-29.
for patients with irritable bowel syndrome withoutet al.Rifaximin therapy
55.constipation. Chey WD, Maneerattaporn M, Saad R. Pharmacologic and
N Engl J Med2011; 364: 22-32.
complementary and alternative medicine therapies for56.irritable bowel syndrome. Awad RA, Camacho S. AGut Liver2011; 5: 253-266.
placebo-controlled trial of polyethylene glycol effects on
randomized, double-blind,
599
fasting and postprandial rectal sensitivity and symptoms inhypersensitive constipation-predominant irritable bowel57.syndrome. Manabe N, Rao AS, Wong BS, Camilleri M. EmergingColorectal Dis2010; 12: 1131-1138.
pharmacologic therapies for irritable bowel syndrome. 58.Gastroenterol RepCamilleri M. New receptor targets for medical therapy in2010; 12: 408-416.
Currirritable bowel syndrome. 59.31: 35-46.
Aliment Pharmacol Ther2010;Pohl D, Tutuian R, Fried M. Pharmacologic treatment ofconstipation: what is new? 60.724-728.
Curr Opin Pharmacol2008; 8:Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy oftricyclic antidepressants in irritable bowel syndrome: a61.
meta-analysis. Gale JD, Houghton LWorld J Gastroenterol2009; 15: 1548-1553.gabapentin and pregabalin: what is the evidence for potentialA. Alpha 2 delta (α(2)δ) ligands,use of these ligands in irritable bowel syndrome. 62.
PharmacolFrontWhelan K. Probiotics and prebiotics in the management of2011; 2: 28.
irritable bowel syndrome: a review of recent clinical trialsand systematic reviews. 63.2011; 14: 581-587.
Curr Opin Clin Nutr Metab CareSainsbury A, Ford AC. Treatment of irritable bowelsyndrome: beyond fiber and antispasmodic agents. Therap64.
Adv GastroenterolYoon SL, Grundmann O, Koepp L, Farrell L. Management2011; 4: 115-127.
of irritable bowel syndrome (IBS) in adults: conventionaland complementary/alternative approaches. 65.
2011; 16: 134-151.
Altern Med RevMagge S, Lmedicine for the irritable bowel syndrome. embo A. Complementary and alternativeClin North Am2011; 40: 245-253.GastroenterolRAeccceeipvteedd::September 19, 2011November 23, 2011
of Medicine, Thuringia Clinic Saalfeld, Teaching Hospital ofAuthor's address: Prof. Peter C. Konturek, MD, Departmentthe University of Jena, Rainweg 68, 07318 Saalfeld, Germany;E-mail: pkonturek@thueringen-kliniken.de